James M Ervasti

Title: Innovations of James M. Ervasti

Introduction

James M. Ervasti is a prominent inventor based in Iowa City, IA (US). He has made significant contributions to the field of biomedical research, particularly in the study of dystrophin and its implications in muscular dystrophy. With a total of 5 patents, his work has advanced the understanding of muscle-related diseases.

Latest Patents

One of his latest patents involves the development of polyclonal and monoclonal antibodies against a 43 kDa dystrophin. This invention discloses methods for preparing antibodies that specifically bind to a 43 kDa dystrophin-associated protein. The molecular weight of this protein is determined through electrophoretic separation under denaturing conditions, followed by transfer to a solid support and staining with wheat germ agglutinin. The method includes administering the peptide PKNMTPYRSPPPYVP (SEQ ID NO: 15) to stimulate an immune response. Another significant patent pertains to the purification of pure, native dystrophin from mammalian skeletal muscle. This invention also includes a method for diagnosing muscular dystrophy by detecting the loss or abnormal structure of dystrophin, which is indicative of the disease.

Career Highlights

James M. Ervasti is affiliated with the University of Iowa Research Foundation, where he conducts his research. His work has been instrumental in advancing the understanding of muscular dystrophy and developing potential diagnostic methods.

Collaborations

He has collaborated with notable colleagues such as Kevin P. Campbell and Steven D. Kahl, contributing to a rich environment of innovation and research.

Conclusion

James M. Ervasti's contributions to the field of biomedical research, particularly in the area of dystrophin and muscular dystrophy, highlight his role as a significant inventor. His patents reflect a commitment to advancing medical science and improving diagnostic methods for muscle-related diseases.